C. Chouaïd

Research interests

Publications

• Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

  Journal of Thoracic Oncology · 2022 · 10.1016/j.jtho.2022.10.003

• Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018

  Journal of Thoracic Oncology · 2020 · 10.1016/j.jtho.2019.12.129

• Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

  Journal of Thoracic Oncology · 2019 · https://doi.org/10.1016/j.jtho.2019.10.013

• Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study

  Arthritis & Rheumatology · 2019 · https://doi.org/10.1002/art.41068

• Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)32222-6

• Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30144-x

• Lung cancer and interstitial lung disease: a literature review

  Journal of Thoracic Disease · 2018 · 10.21037/jtd.2018.05.75

• Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.63.5839

• TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00483-0

• Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)70054-9

• Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

  Clinical Cancer Research · 2015 · 10.1158/1078-0432.ccr-14-2082

• Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.45.6095

• Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2011.39.9782

• Shortened Telomeres in Circulating Leukocytes of Patients with Chronic Obstructive Pulmonary Disease

  American Journal of Respiratory and Critical Care Medicine · 2009 · 10.1164/rccm.200809-1398oc

Current projects

No projects listed.